| Previous Close | 19.01 |
| Open | 18.60 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 900 |
| Day's Range | 17.57 - 19.33 |
| 52 Week Range | 15.09 - 19.67 |
| Volume | 88,105 |
| Avg. Volume | 248,871 |
| Market Cap | 457.882M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -72.63 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
MONTREAL and CHARLOTTE, N.C. , May 14, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that the underwriters for its initial public offering of common shares have fully exercised their option to purchase an additional 825,000 common shares at the public offering price of $15.00 per share. The gross proceeds to Milestone from the exercise of the option, are expected to be approximately $12.4 million , bringing the total gross proceeds of Milestone's initial public offering to approximately $94.9 million before deducting underwriting discounts, commissions and offering expenses. All of the common shares were offered by Milestone.
MONTREAL and CHARLOTTE, N.C. , May 13, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the closing of its previously announced initial public offering of 5,500,000 of its common shares at a public offering price of $15.00 per share. The gross proceeds to Milestone, before deducting underwriting discounts, commissions and offering expenses, were approximately $82.5 million . All of the common shares were offered by Milestone.
MONTREAL and CHARLOTTE, N.C. , May 8, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the pricing of its upsized initial public offering of 5,500,000 of its common shares at a public offering price of $15.00 per share. The gross proceeds to Milestone, before deducting underwriting discounts, commissions and offering expenses, are expected to be approximately $82.5 million . All of the common shares are being offered by Milestone. In addition, Milestone has granted certain of the underwriters a 30-day option to purchase up to 825,000 additional common shares at the initial public offering price, less the underwriting discounts and commissions.
There’s a new pharma investment on the Street. The IPO Milestone Pharmaceuticals Inc. will issue 5 million shares on the Nasdaq under ticker MIST, according to the firm’s S-1 filing. Priced between $14 ...